Covid-19
Dr Reddy Labs enters in voluntary licensing agreement with Eli Lilly to access it’s Covid treatment in India
Hyderabad/UNI: Dr Reddy’s Laboratories on Wednesday announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company (“Lilly”) for the manufacture and commercialization of the drug Baricitinib in India.
The drug Baricitinib has received restricted emergency use approval from the Central Drugs Standard Control Organization (CDSCO), for use in combination with Remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 among hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), the Hyderabad based pharmaceutical giant said.
This partnership comes at a critical juncture in the fight against the increasing Covid-19 caseload in India, as it adds to the company’s existing range of COVID-19 therapeutics covering the full spectrum from mild to moderate and severe conditions of the disease.
Deepak Sapra, Chief Executive Officer, API and Services, Dr Reddy’s Laboratories, said, "From the start, we have been determined to explore every possible avenue against COVID-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India.”
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
